Swahili
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

paris/maumivu ya kichwa

Kiungo kimehifadhiwa kwenye clipboard
Ukurasa 1 kutoka 40 matokeo

[Headache Emergency Center, Paris, Lariboisiere Hospital].

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia

[Cathinones use in Paris].

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND The pattern of recreational drug use has changed over the last decade and now includes a multitude of substances sold as "research chemicals" or new psychoactive substances, "NPS". In France, synthetic cathinones emerged in 2008 (while first mentioned by the French police force in 2007

[Neuromeningeal tuberculosis in northeastern suburbs of Paris. Nineteen cases].

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
METHODS Analyze characteristics of neuromeningeal tuberculosis in the northeastern suburbs of Paris. METHODS Retrospective study of 19 observations between 1988 and 1999. RESULTS Thirteen cases of meningitis, 3 cases of meningitis associated with a tuberculoma and 3 cases with isolated tuberculoma

Shaping a pain-free future for cluster headache patients. The Declaration of Paris.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia

[6th Congress of Therapy and Neurology: Headaches. Paris, France, 3-4 December 1999. Proceedings].

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia

Proceedings of the 6th International Headache Congress. Paris, France, 26-29 August 1993. Abstracts.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia

A comprehensive picture of 4-year outcome of severe brain injuries. Results from the PariS-TBI study.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
OBJECTIVE Survivors of severe traumatic brain injury have a great variety of impairments and participation restrictions. Detailed descriptions of their long-term outcome are critical. We aimed to assess brain injury outcome for subjects with traumatic brain injury in terms of the International

[Trichinosis: review of the epidemic in the south suburbs of Paris in January, 1976 (apropos of 125 cases)].

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
The authors report the results of the trichinosis epidemic which occurred in the southern suburbs of Paris in January 1976. 125 patients from a total of 65 families were affected. The major signs: oedema of the face and eyelids, fever and myalgia, were commonly found. There were even laboratory

Clinical features of 1487 COVID-19 patients with outpatient management in the Greater Paris: the COVID-call study

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
Clinical features of COVID-19 have been mostly described in hospitalized patients with and without ICU admission. Yet, up to 80% of patients are managed in an outpatient setting. This population is poorly documented. In France, health authorities recommend outpatient management of patients
A total of 69 patients with primary Raynaud phenomenon were included in a multicenter, randomized, double-blind, crossover, placebo-controlled trial to assess the efficacy of nicardipine, a new calcium channel blocker. The trial data were combined with a meteorological survey. Nicardipine
Nitroglycerin (NTG) (glyceryl trinitrate) was synthesized by the Italian chemist Ascanio Sobrero in Paris in 1846. A very unstable explosive, Alfred Nobel while working on explosives, combined it with Kiselguhr and patented it as dynamite in 1867. NTG was introduced in 1879 in medicine in the

The Emergency Headache Center at the Lariboisière Hospital: 7 years with more than 70,000 patients.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
After 7 years and 70,000 patients of whom two-thirds women and one-third men, 77% aged 20-50 years, 90% residing in Paris or the suburban areas, we report our experience at the Lariboisière hospital Emergency headache Center. About two-thirds of our patients complained of primary headache, i.e.,

Huygens' headache.

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND Christiaan Huygens (1629-1695) was a Dutch mathematician, physicist, and astronomer. He became well-known as inventor of the pendulum clock and described light as a wave phenomenon. He became Fellow of the Royal Society (London) and member of the Académie des Sciences (Paris). From the
OBJECTIVE The aim of this study was to examine the course of headache diagnosis, headache frequency, anxiety, comorbid depressive symptoms and school absenteeism in adolescents with migraine and tension-type headaches five years after baseline. METHODS We followed a group of 122 children with a mean
To evaluate the relationship among quality of life, temperament, illness perception, and mental turmoil in patients affected by chronic daily headache with concomitant medication overuse headache. Participants were 116 consecutive adult outpatients admitted to the Department of General Medicine of
Jiunge na ukurasa
wetu wa facebook

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi

  • Inafanya kazi katika lugha 55
  • Uponyaji wa mitishamba unaungwa mkono na sayansi
  • Kutambua mimea kwa picha
  • Ramani ya GPS inayoshirikiana
  • Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
  • Tafuta mimea ya dawa na athari zao
  • Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu

Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa

Google Play badgeApp Store badge